MINNEAPOLIS, Aug. 1, 2023 /PRNewswire/ — MEKanistic Therapeutics, a pioneering biotechnology company revolutionizing kinase inhibitors for cancer treatment, announced today that its investigational cancer clinical candidate MTX-531 has been approved for receiving continued development…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.